- Home
- KALV vs MYGN Comparison
KALV vs MYGN Comparison
Compare KALV & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- MYGN
- Stock Information
- Founded
- KALV N/A
- MYGN 1991
- Country
- KALV United States
- MYGN United States
- Employees
- KALV N/A
- MYGN N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KALV Health Care
- MYGN Health Care
- Exchange
- KALV Nasdaq
- MYGN Nasdaq
- Market Cap
- KALV 796.4M
- MYGN 642.0M
- IPO Year
- KALV N/A
- MYGN 1995
- Fundamental
- Price
- KALV $13.50
- MYGN $7.50
- Analyst Decision
- KALV Strong Buy
- MYGN Hold
- Analyst Count
- KALV 8
- MYGN 13
- Target Price
- KALV $26.43
- MYGN $13.50
- AVG Volume (30 Days)
- KALV 1.0M
- MYGN 1.4M
- Earning Date
- KALV 09-11-2025
- MYGN 11-06-2025
- Dividend Yield
- KALV N/A
- MYGN N/A
- EPS Growth
- KALV N/A
- MYGN N/A
- EPS
- KALV N/A
- MYGN N/A
- Revenue
- KALV $1,426,000.00
- MYGN $832,900,000.00
- Revenue This Year
- KALV N/A
- MYGN $0.17
- Revenue Next Year
- KALV $213.43
- MYGN $6.19
- P/E Ratio
- KALV N/A
- MYGN N/A
- Revenue Growth
- KALV N/A
- MYGN 3.83
- 52 Week Low
- KALV $7.30
- MYGN $3.76
- 52 Week High
- KALV $17.28
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- KALV 44.26
- MYGN 68.28
- Support Level
- KALV $13.26
- MYGN $7.13
- Resistance Level
- KALV $17.28
- MYGN $7.80
- Average True Range (ATR)
- KALV 1.03
- MYGN 0.43
- MACD
- KALV -0.10
- MYGN 0.06
- Stochastic Oscillator
- KALV 9.13
- MYGN 85.15
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.